Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing.
Division of Nephrology, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Nanfang Hospital, Southern Medical University, Guangzhou.
Eur J Emerg Med. 2021 Jun 1;28(3):189-195. doi: 10.1097/MEJ.0000000000000812.
Thiamine and vitamin C have been increasingly used in patients with sepsis or septic shock because of their potential for improving metabolism and reducing mortality.
We aim to determine if thiamine combined vitamin C can reduce mortality in patients with sepsis or septic shock.
We comprehensively searched the PubMed, Embase, Cochrane Library, and Web of Science databases from their inception dates through 1 January 2021. Literature works evaluating the efficacy of thiamine combined vitamin C in patients with sepsis or septic shock were considered.
Two reviewers extracted data and assessed study quality. A meta-analysis was performed to calculate an odds ratio (OR), 95% confidence intervals (CIs), and P values for in-hospital mortality (primary outcome). Secondary outcomes included duration of ICU stay, duration of hospital stay, duration of vasopressor use, and change in sequential organ failure assessment (SOFA) scores.
Seven randomized controlled trials were identified, encompassing a total of 868 patients. There was no statistical difference between groups for in-hospital mortality (OR: 1.11; 95% CI [0.79-1.56]; P = 0.55). Other than improving SOFA score during the first 72 h after enrollment and duration of vasopressor use, we found no other significant associations.
Despite widespread enthusiasm for thiamine combined with vitamin C for sepsis and septic shock, we only found an association with reduced SOFA score and time of vasopressor use. There was no association with in-hospital mortality.
由于硫胺素和维生素 C 具有改善代谢和降低死亡率的潜力,因此它们在脓毒症或感染性休克患者中的应用越来越多。
我们旨在确定硫胺素联合维生素 C 是否可以降低脓毒症或感染性休克患者的死亡率。
我们全面检索了 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库,检索时间从建库至 2021 年 1 月 1 日。评估硫胺素联合维生素 C 治疗脓毒症或感染性休克患者疗效的文献均被视为研究对象。
两名审查员提取数据并评估研究质量。使用 Meta 分析计算院内死亡率(主要结局)的优势比(OR)、95%置信区间(CI)和 P 值。次要结局包括 ICU 住院时间、医院住院时间、血管加压素使用时间和序贯器官衰竭评估(SOFA)评分变化。
共纳入 7 项随机对照试验,总计纳入 868 例患者。两组间院内死亡率无统计学差异(OR:1.11;95%CI [0.79-1.56];P=0.55)。除了在纳入后 72 小时内改善 SOFA 评分和血管加压素使用时间外,我们没有发现其他显著关联。
尽管人们对硫胺素联合维生素 C 治疗脓毒症和感染性休克寄予厚望,但我们仅发现与降低 SOFA 评分和血管加压素使用时间有关,与院内死亡率无关。